T-cells capable of reacting to mutations in cancer patients have potential use as therapeutics. Identifying and isolating these cells from patients is a crucial step in developing these treatments. Researchers at the National Cancer Institute (NCI) have developed a novel method of isolating mutation-reactive T-cells from a patient’s peripheral blood lymphocytes (PBL). The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this method of isolating mutation-reactive T-cells from peripheral blood.
Inventors at the National Cancer Institute (NCI) have developed chimeric antigen receptors (CARs) that target two B cell surface antigens, CD19 and CD22, improving treatment of B-cell malignancies, such as acute lymphoblastic leukemia (ALL). NCI is actively seeking parties interested in licensing this invention to commercialist the bicistronic CAR construct targeting CD19 and CD22 for immunotherapy.
There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have designed novel chimeric adaptor proteins (CAPs) consisting of signaling molecules downstream of the T cell receptor (TCR) for use in T cell-mediated immunotherapy. NCI is seeking parties interested in licensing and/or co-developing CAPs that can be used in immunotherapy for treating cancer, including both hematological and solid malignancies.
Researchers at the NCI have developed chimeric antigen receptors (CARs) with a high affinity for mesothelin to be used as an immunotherapy to treat pancreatic cancer, ovarian cancer, and mesothelioma. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients.
NCI researchers developed a combination therapy of histone deacetylase (HDAC) inhibitors and immunotherapies, such as checkpoint inhibitors, virus-based vaccines, monoclonal antibodies, cell-based treatments or radiopharmaceuticals. The NCI Laboratory of Tumor Immunology and Biology seeks parties to license or co-develop this method.
Researchers at the National Cancer Institute developed a novel method of immunogenic modulation in androgen and endocrine deprivation therapy. A combination of hormone therapy with immunotherapies such as PROSTVAC™, a Brachyury vaccine, PROVENGE™, ipilumimab, nivolumab, XOFIGO™, PANVAC, a yeast-MUC-1 immunotherapeutic, or HERCEPTIN™ can benefit prostate and breast cancer patients, especially those who have acquired resistances. The researchers seek parties to co-develop this method.
NCI researchers have identified novel compounds that inhibit FKBP52-mediated activation of the androgen receptor protein (AR), a major target for anti-prostate cancer therapeutic development. As FKBP52 is implicated in the regulation of other hormone receptors, anti-FKBP52 may be applicable in the treatment of hormone-dependent diseases such as diabetes or even used as contraceptives. NCI seeks partners to license or co-develop this technology.
Scientists at the National Cancer Institute (NCI) developed a novel stealth lipid-based nanoparticle formulation comprising phospholipid, DC8,9PC and a polyethylene glycol-ated (PEGylated) lipid – such as DSPE-PEG2000 – that efficiently package a high amounts of hydrophobic photodynamic drug (PDT) – such as HPPH – in stable vesicles. This HPPH-loaded liposome system demonstrates higher serum stability and ambient temperature stability upon storage. It exhibits increased tumor accumulation and improved animal survival in mice tumor models compared to the formulation in current clinical trials. The NCI seeks co-development partners and/or corporate licensees for the application of the technology as an anti-cancer therapeutic.
Researchers at the National Cancer Institute (NCI) developed cell free methods for efficiently producing high titer, papillomavirus virus-based gene transfer vectors. These vectors can potentially be used for vaccines and/or cancer therapeutic applications. NCI seeks licensing and/or co-development research collaborations for further development of these vectors.
Multi-potential hematopoietic progenitor cells (HPC) can differentiate into any class of blood cells, and are highly useful in regenerative medicine, immunology, and cancer immunotherapy. Current methods to generate HPCs are limited either due to the use of animal products, or the high cost and low efficiency of animal product free systems. Researchers at the National Cancer Institute (NCI) have developed a protocol to prepare HPCs from human induced pluripotent stem cells (hiPSC), using human mesenchymal stem cells (hMSC) in a three-dimensional (3D) co-culture condition. Thus, they are able to generate HPCs in a fully human, autologous system, which can be used to further generate immune cells for therapy. This protocol is adaptable to mass production by bioreactors. NCI seeks licensees for these methods of generating HPCs in a 3D co-culture with hMSCs to be used in a variety of applications such as treatment of blood disorders, regenerative medicine, and antibody production.
Researchers at the National Cancer Institute (NCI) developed several high-affinity monoclonal antibodies to treat Fibroblast Growth Factor Receptor 4 (FGFR4)-related diseases including rhabdomyosarcoma and cancers of the liver, lung, pancreas, ovary and prostate. These antibodies have been used to generate antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), which are capable of specifically targeting and killing diseased cells. NCI seeks co-development opportunities or licensees for this technology.
Researchers at the National Cancer Institute (NCI) seek research collaborations or licensees for a monoclonal antibody targeting CD276, also known as B7-H3, and related conjugates. The antibody and antibody drug conjugates (ADC) containing the antibody of the current invention were tested in vivo and have potential for use in cancer immunotherapy.
Researchers at the National Cancer Institute (NCI) seek research collaborations or licensees for a monoclonal antibody targeting TEM8 and related conjugates. The antibody and antibody drug conjugates (ADC) containing the antibody of the current invention were tested in vivo and have potential for use in cancer immunotherapy.
Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target B-cell maturation antigen (BCMA) are strong therapeutic candidates for patients with plasma cell malignancy diseases such as, multiple myeloma (MM), as well as for patients with Hodgkin’s lymphoma. BCMA is a cell surface protein preferentially expressed on a subset of B cells and mature plasma cells, but not on other cells in the body. The limited expression of BCMA on B and plasma cells makes BCMA an attractive therapeutic target for B cell and plasma cell malignancy diseases. The 12 anti-BCMA CARs described are fully human CARS and have the potential to treat patients with various plasma cell and B cell malignancy diseases.
Novel fusion proteins with good stability and potency against HIV-1. These fusion proteins have good drug properties and potential as prophylactics or therapeutics against HIV-1 infection. Researchers at the NCI seek licensing for the development and commercialization of novel fusion proteins as therapeutics or prophylactics against HIV-1 infection.
There is a marked increase in immunosuppressive myeloid progenitors and myeloid cells in tumors and at metastatic tissue sites, rendering these types of cells useful in cancer therapeutics, especially after genetic modifications that improve their anti-tumor properties further. The National Cancer Institute (NCI) seeks research co-development or licensing partners to further develop genetically engineered myeloid cells (GEMys) for use in cancer immunotherapy.